loading
Sonnet Biotherapeutics Holdings Inc stock is traded at $1.30, with a volume of 7,970. It is up +0.78% in the last 24 hours and up +3.17% over the past month. Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
See More
Previous Close:
$1.29
Open:
$1.29
24h Volume:
7,970
Relative Volume:
0.18
Market Cap:
$4.12M
Revenue:
$129.20K
Net Income/Loss:
$-7.44M
P/E Ratio:
-0.1162
EPS:
-11.19
Net Cash Flow:
$-8.62M
1W Performance:
-2.26%
1M Performance:
+3.17%
6M Performance:
-57.24%
1Y Performance:
-91.17%
1-Day Range:
Value
$1.29
$1.3195
1-Week Range:
Value
$1.21
$1.3498
52-Week Range:
Value
$1.10
$16.00

Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile

Name
Name
Sonnet Biotherapeutics Holdings Inc
Name
Phone
609-375-2227
Name
Address
100 OVERLOOK CENTER, PRINCETON, NJ
Name
Employee
13
Name
Twitter
@SonnetBio
Name
Next Earnings Date
2024-08-12
Name
Latest SEC Filings
Name
SONN's Discussions on Twitter

Compare SONN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SONN
Sonnet Biotherapeutics Holdings Inc
1.30 4.08M 129.20K -7.44M -8.62M -11.19
Biotechnology icon
ONC
Beigene Ltd Adr
230.69 25.21B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
436.12 112.83B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.285 40.72M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
587.85 62.15B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
71.50 5.75B 0 -153.72M -103.81M -2.00

Sonnet Biotherapeutics Holdings Inc Stock (SONN) Latest News

pulisher
May 16, 2025

Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025
pulisher
May 13, 2025

Sonnet BioTherapeutics Holdings, Inc. SEC 10-Q Report - TradingView

May 13, 2025
pulisher
May 11, 2025

Sonnet BioTherapeutics (SONN) Expected to Announce Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 01, 2025

Sonnet Chief Medical Officer, Richard Kenney, M.D., to - GlobeNewswire

May 01, 2025
pulisher
May 01, 2025

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit - The Globe and Mail

May 01, 2025
pulisher
Apr 19, 2025

Chanticleer Holdings Little Big Burger Partner and Brand Ambassador Denny Hamlin Wins the Daytona 500 - marketscreener.com

Apr 19, 2025
pulisher
Apr 16, 2025

Sonnet Releases Virtual Investor "What This Means" Segment | SONN Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Sonnet BioTherapeutics Discusses Positive Safety Data for SON-1010 in Virtual Investor Segment - Nasdaq

Apr 16, 2025
pulisher
Apr 16, 2025

Sonnet Releases Virtual Investor "What This Means" Segment - GlobeNewswire

Apr 16, 2025
pulisher
Apr 15, 2025

Biotech Leader Dr. Pankaj Mohan Honored on NASDAQ After Tragic Crash - newsindiatimes.com

Apr 15, 2025
pulisher
Apr 08, 2025

Sonnet BioTherapeutics (NASDAQ:SONN) Receives Buy Rating from Chardan Capital - Defense World

Apr 08, 2025
pulisher
Apr 07, 2025

SONN stock touches 52-week low at $1.18 amid market challenges - Investing.com India

Apr 07, 2025
pulisher
Apr 07, 2025

Sonnet BioTherapeutics reports positive results from ovarian cancer therapy trial - Yahoo Finance

Apr 07, 2025
pulisher
Apr 06, 2025

Sonnet BioTherapeutics advances in cancer trial - Investing.com Australia

Apr 06, 2025
pulisher
Apr 04, 2025

Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up - MarketScreener

Apr 04, 2025
pulisher
Apr 04, 2025

Sonnet BioTherapeutics advances in cancer trial By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

Sonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab combo - TipRanks

Apr 04, 2025
pulisher
Apr 04, 2025

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose - The Manila Times

Apr 04, 2025
pulisher
Apr 04, 2025

Sonnet'S Son-1010 Demonstrates A Strong Safety Profile In Combination With Atezolizumab For Treatment Of Platinum-Resistant Ovarian Cancer - MarketScreener

Apr 04, 2025
pulisher
Apr 04, 2025

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in - GlobeNewswire

Apr 04, 2025
pulisher
Apr 02, 2025

Sonnet BioTherapeutics appoints interim CEO and new president By Investing.com - Investing.com Canada

Apr 02, 2025
pulisher
Apr 01, 2025

Sonnet Announces Release of Corporate Update Video - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet BioTherapeutics appoints interim CEO and new president - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet BioTherapeutics Announces New Interim CEO Appointment - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Pilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech Company - NewsBreak: Local News & Alerts

Apr 01, 2025
pulisher
Apr 01, 2025

Pilot killed in N.J. plane crash was biotech company founder, CEO - NJ.com

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - citybiz

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet BioTherapeutics appoints interim CEO after founder’s death - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet Announces The Passing Of Founder And CEO Pankaj Mohan - marketscreener.com

Apr 01, 2025
pulisher
Mar 30, 2025

Chardan Capital Reaffirms Buy Rating for Sonnet BioTherapeutics (NASDAQ:SONN) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Sonnet BioTherapeutics’ (SONN) Buy Rating Reaffirmed at Chardan Capital - The AM Reporter

Mar 29, 2025
pulisher
Mar 28, 2025

SONN stock touches 52-week low at $1.28 amid market challenges - Investing.com Australia

Mar 28, 2025
pulisher
Mar 27, 2025

Sonnet BioTherapeutics Successfully Completes First Safety - GlobeNewswire

Mar 27, 2025
pulisher
Mar 26, 2025

Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Clinical Trial Success: New Cancer Drug Combo Shows 83% Disease Control in Sarcoma Patients - Stock Titan

Mar 26, 2025
pulisher
Mar 21, 2025

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Up 16.4% in February - Defense World

Mar 21, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics secures new IL-18 patent - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics secures new IL-18 patent By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics Secures Second Patent for IL-18 Variant - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics Receives Notice of Allowance for - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein - Yahoo

Mar 19, 2025
pulisher
Mar 11, 2025

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Sonnet BioTherapeutics Holdings, Inc. Announces Availability of On-Demand Video Webcast Following Virtual Investor "Top 5 for ‘25" Conference - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Sonnet Bio CEO Unveils 5 Game-Changing Developments Coming in 2025 - StockTitan

Mar 11, 2025

Sonnet Biotherapeutics Holdings Inc Stock (SONN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.26
price up icon 0.00%
$570.58
price up icon 0.93%
$32.06
price up icon 3.69%
$3.905
price up icon 1.50%
$290.53
price up icon 1.73%
$70.81
price down icon 1.04%
Cap:     |  Volume (24h):